1,377 件 ・ 関連度順
概要と使いどころ
Recommends early delivery based on individualized risk assessment rather than expectant management for pregnant patients with preexisting diabetes mellitus (PDM). Consider when evaluating delivery timing in the presence of diabetes‑related complications, suboptimal glycemia, abnormal fetal growth, or maternal comorbidities that may increase perinatal risk beyond 38 weeks gestation.
日本語の概要は準備中です。原文の説明を表示しています。
Performs a structured pre‑prescription evaluation of mental/psychological status, prior diabetes self‑care adherence, willingness/interest in CSII, and availability for follow‑up visits. Triggers include: 'Evaluating pump candidacy', 'Pre‑pump checklist: psych, adherence, motivation, follow-up'.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends unilateral resection by an experienced adrenal surgeon for all cases of benign unilateral disease causing Cushing's syndrome. Trigger when a CS patient has a unilateral adrenal lesion confirmed benign via imaging and biochemical assessment.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends obtaining a postoperative pituitary MRI within 1–3 months after successful transsphenoidal surgery (TSS) to establish a new baseline for future recurrence assessment. Use when a Cushing’s syndrome patient has achieved biochemical remission post‑TSS and is entering routine follow‑up.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends obtaining serum free T4 and prolactin levels within 1–2 weeks after transsphenoidal surgery (TSS) for Cushing's syndrome to screen for overt hypopituitarism. Use in postoperative Cushing's syndrome patients during the early recovery window when evaluating for new pituitary hormone deficiencies.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends follow-up morning cortisol and/or ACTH stimulation tests or insulin-induced hypoglycemia to assess HPA axis recovery in postoperative Cushing's syndrome patients with at least one intact adrenal gland. Triggers include postoperative remission (morning cortisol <5 µg/dL or UFC <28–56 nmol/d) and the need to evaluate HPA recovery before glucocorticoid discontinuation.
日本語の概要は準備中です。原文の説明を表示しています。
This skill outlines monitoring of mineralocorticoid replacement in primary adrenal insufficiency, focusing on clinical assessment of salt craving, postural hypotension, or edema alongside serum electrolyte measurements. It is initiated when evaluating patients on fludrocortisone therapy to ensure adequate dosing and avoid over- or under-replacement.
日本語の概要は準備中です。原文の説明を表示しています。
Monitors glucocorticoid replacement in primary adrenal insufficiency (PAI) patients using clinical assessment of body weight, postural blood pressure, energy levels, and signs of frank glucocorticoid excess. Trigger phrases include "PAI patient on glucocorticoid replacement," "assess for weight gain or insomnia," and "evaluate for postural hypotension or fatigue."
日本語の概要は準備中です。原文の説明を表示しています。
This skill outlines monitoring glucocorticoid replacement in children with primary adrenal insufficiency (PAI) using clinical assessment of growth velocity, weight, blood pressure, and energy levels. Trigger when evaluating a child with PAI for adequacy of glucocorticoid therapy during routine follow-up.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends performing biochemical testing for HPA axis at least 18-24 hours after last hydrocortisone dose or longer for synthetic glucocorticoids. Use when scheduling HPA axis testing in glucocorticoid-treated patient needing assessment of adrenal reserve.
日本語の概要は準備中です。原文の説明を表示しています。
Guide a non-stigmatising pediatric obesity consultation using the 5As framework (Ask, Assess, Advise, Agree, Assist) and 4Ms assessment (Metabolic, Mechanical, Mental Health, Social Milieu), based on the CMAJ 2025 guideline. Trigger when a clinician asks how to approach a weight conversation with a child or family, how to use the 5As for obesity, how to assess a child with obesity, or how to conduct a non-judgmental obesity visit.
日本語の概要は準備中です。原文の説明を表示しています。
Calculate and interpret the PREVENT-ASCVD risk score (10-year and 30-year) for primary prevention of atherosclerotic cardiovascular disease per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers inputs required, risk-category thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%), when to use the 30-year calculation (adults 30–59), and how PREVENT differs from the older Pooled Cohort Equations (lower risk estimates by 40–50%, race-agnostic). Use when a clinician asks what the 10-year ASCVD risk is, how to calculate PREVENT, PCE vs PREVENT, risk category for this patient, does my patient need a statin, 30-year risk calculation, primary prevention risk assessment. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.
日本語の概要は準備中です。原文の説明を表示しています。
This skill should be used when the user asks to "implement LLM-as-judge", "compare model outputs", "create evaluation rubrics", "mitigate evaluation bias", or mentions direct scoring, pairwise comparison, position bias, evaluation pipelines, or automated quality assessment.
日本語の概要は準備中です。原文の説明を表示しています。
Testing and benchmarking LLM agents including behavioral testing, capability assessment, reliability metrics, and production monitoring—where even top agents achieve less than 50% on real-world benchmarks
日本語の概要は準備中です。原文の説明を表示しています。
Analyze the current uncommitted diff and give a detailed summary with risk assessment. Use when asking what changed, reviewing changes before a commit, or requesting a change summary.
日本語の概要は準備中です。原文の説明を表示しています。
Expert-level clinical engineering covering medical equipment management, hospital technology systems, healthcare IT integration, safety standards, and health technology assessment.
日本語の概要は準備中です。原文の説明を表示しています。
Code comment accuracy verification, documentation completeness assessment, comment rot detection.
日本語の概要は準備中です。原文の説明を表示しています。
Code comment accuracy verification, documentation completeness assessment, comment rot detection.
日本語の概要は準備中です。原文の説明を表示しています。
Enforce traceability from natural-language intent to machine predicates, final observables, evidence, and owner-readable acceptance. Use when conducting any audit, review, QA pass, parity or compliance check, security assessment, code or architecture review, visual or behavioral comparison, data validation, system verification, completion gate, or claim that an implementation satisfies a human request.
日本語の概要は準備中です。原文の説明を表示しています。
Specialized GitHub PR intelligence agent for automatically gathering comprehensive context from Pull Requests. Activate when users need CI failure analysis, review comment investigation, or PR status assessment. Triggers on requests like "CI 실패 원인 찾아줘", "gather review comments", "check PR status", "analyze PR".
日本語の概要は準備中です。原文の説明を表示しています。
[Content] Use when you need to build structured learning/teaching course material with Bloom taxonomy objectives, modules, lessons, exercises, and assessments.
日本語の概要は準備中です。原文の説明を表示しています。
Turns company records into structured company research summaries. Use when the user provides company names or records and wants a consistent overview, market position, and relevance assessment.
日本語の概要は準備中です。原文の説明を表示しています。
医学证据等级排序与编排层 skill - evidence grading orchestrator. 当用户请求"证据等级 / GRADE / 证据排序 / 医学证据评估 / 系统评价排序 / 临床证据排序 / 证据金字塔 / 给 PMID 打分 / Practice Guideline 优先 / Cochrane 优先 / 反向证据交叉验证 / evidence grading / quality of evidence / evidence pyramid / GRADE assessment / Cochrane review ranking / clinical evidence ranking"时,**调用本 skill 进行医学证据自动分级,自动选择最佳信息源**。本 skill 是编排层(L2)·不直接打 NCBI/Europe PMC/ClinicalTrials API,而是编排 6 个底层原子 skill(pubmed-eutils / europepmc-search / clinical-trials-v2 / aact-bulk-trials / bioc-fulltext-fetch / pubtator-entity-search)的召回结果,按证据金字塔(指南 > Meta > RCT > Cohort > Case-Control > Case Report)做 GRADE A/B/C/D 自动评级,自动剔除 editorial/letter/comment。优先使用 BioMCP MCP server 做 fan-out(genomoncology/biomcp);无 BioMCP 时走自建 slow-path 兜底。跨平台无锁(Claude Code / Codex / Gemini CLI)。
日本語の概要は準備中です。原文の説明を表示しています。
Content quality and E-E-A-T assessment for AI citability — evaluate experience, expertise, authoritativeness, trustworthiness, and content structure
日本語の概要は準備中です。原文の説明を表示しています。